site stats

Paragon 2 trial anzgog

WebJun 7, 2024 · Introducing PARAGON-II, a new trial for women with rare gynaecological cancers. 07 Jun 2024 ANZGOG’s rare tumour, basket study, PARAGON-II, has officially … WebApr 10, 2024 · Ces données rétrospectives ont été confirmées dans le premier essai prospectif de phase 2, l’étude PARAGON-ANZGOG0309. ... the PARAGON/ANZGOG 0903 trial. Gynecol Oncol, 163 (2024), pp. 72-78, 10.1016/j.ygyno.2024.07.024. View PDF View article View in Scopus Google Scholar [43]

A phase 2 study of anastrozole in patients with oestrogen …

WebSep 1, 2024 · PARAGON (ANZGOG-0903): A phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression Project:... WebThe Paragon study is a basket protocol that includes a series of phase 2 trials investigating the activity of anastrozole in patients with estrogen or progesterone receptor–positive recurrent gynecological cancers. We report the results of treatment in patients with platinum-resistant or -refractory recurrent epithelial ovarian cancer. daugherty\\u0027s decatur il https://ambiasmarthome.com

Introducing PARAGON-II, a new trial for women with rare …

WebAug 16, 2024 · PARAGON is an investigator-initiated single-arm open-label multicentre phase 2 trial, designed to evaluate the activity of anastrozole in post-menopausal … WebMay 20, 2024 · The phase 2 PARAGON trial, which investigated anastrozole in a variety of gynecologic cancers, included a cohort of 41 postmenopausal recurrent granulosa cell tumor patients with estrogen... WebThe Paragon study is a basket protocol that includes a series of phase 2 trials investigating the activity of anastrozole in patients with estrogen or progesterone receptor–positive recurrent gynecological cancers. ... Median progression-free survival was 2.7 months (95% CI, 2.0–2.8 months). The median duration of clinical benefit was 2.8 ... daugherty\u0027s drugs pine knot

PARAGON: A Phase II study of anastrozole in patients …

Category:PARAGON: A phase 2 study of anastrozole (An) in patients

Tags:Paragon 2 trial anzgog

Paragon 2 trial anzgog

Phase 2 study of anastrozole in recurrent estrogen …

WebJun 30, 2024 · [email protected] Summary Prof Linda Mileshkin Principal Investigator Vinorelbine is a chemotherapeutic agent that is currently used for treatment of lung and … WebThere is some evidence that a subset of patients with recurrent ovarian cancer may benefit from antiestrogen therapy. The Paragon study is a basket protocol that includes a series …

Paragon 2 trial anzgog

Did you know?

WebMay 20, 2014 · Methods: PARAGON is a Gynecologic Cancer InterGroup phase 2 trial lead by the Australia New Zealand Gynaecological Oncology Group and NHMRC Clinical Trials Centre, in collaboration with Cancer Research UK and the Belgian Gynaecological Oncology Group. The study is designed to facilitate research in rare tumours. http://www.nlm.medscape.idmu.unboundmedicine.unboundmedicine.com/medline/citation/31328463/PARAGON__ANZGOG_0903_:_a_phase_2_study_of_anastrozole_in_asymptomatic_patients_with_estrogen_and_progesterone_receptor_positive_recurrent_ovarian_cancer_and_CA125_progression_

WebOct 24, 2015 · PARAGON- an ANZGOG Phase 2 study of anastrazole in asymptomatic women with estrogen (ER)/progesterone (PR) positive ovarian cancer with GCIG CA125 progression after first line treatment.... WebApr 1, 2024 · 2. Materials and methods PARAGON is a Gynecologic Cancer InterGroup trial led by the Australian New Zealand Gynecological Oncology Group (ANZGOG) and …

WebMay 23, 2024 · Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial – ANZGOG 0903 Linda Mileshkin a, ⁎ ,1 , Richard Edmondson b,c,1 ,RachelL.O'Connell d , Katrin M. Sjoquist d ,JohnAndrews d , WebDec 1, 2024 · 2. Materials and methods PARAGON is a Gynecologic Cancer InterGroup trial led by the Australian New Zealand Gynecological Oncology Group (ANZGOG) and coordinated by the National Health and Medical Research Council (NHMRC) Clinical Trials Centre, University of Sydney.

WebA subset of patients with recurrent ovarian cancer (ROC) may benefit from antiestrogen therapy with higher response rates reported in tumors that are strongly estrogen receptor (ER)-positive (ER⁺). PARAGON is a basket trial that incorporates 7 phase 2 trials investigating the activity of anastrozole in patients with ER⁺ and/or progesterone receptor …

WebPARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 ... PARAGON is an investigator-initiated single arm open-label multicentre phase 2 trial, designed to evaluate the activity of anastrozole in postmenopausal patients with a wide … bkfc uk newcastleWeb129 The PARAGON (ANZGOG-0903) trial is an investigator-initiated basket trial 130 investigating the activity of anastrozole in post-menopausal patients with a wide 131 … daugherty\\u0027s drug store pine knot kybkfc wembley